Identification of a novel methylation gene sites signature to predict prognosis in kidney renal papillary cell carcinoma by comprehensive profiling

CURRENT STATUS: POSTED

yinglei wang
yantai affiliated hospital of binzhou medical university

wangyinglei_doctor@163.com Corresponding Author
ORCiD: https://orcid.org/0000-0001-9920-5687

YingYing Zhang
Office of quality and safety management; YanTai Affiliated hospital of BinZhou Medical University

DOI:
10.21203/rs.3.rs-16370/v1

SUBJECT AREAS
Cancer Biology Oncology

KEYWORDS
Kidney renal papillary cell carcinoma; overall survival; prognosis; signature; methylated sites
Abstract
Most kidney renal papillary cell carcinoma (KIRP) patients are diagnosed at the advanced stage and have a poor prognosis. DNA methylation plays an important role in prognosis prediction of cancers. Identification of novel DNA methylation site biomarkers could be beneficial for the prognosis of KIRP patients. In this study, we aimed to find an efficient methylated sites model for predicting survival in KIRP.

Background
Renal carcinoma is a heterogeneous tumor, of which epithelial renal cell carcinoma (RCC) accounts for the majority of cases. There are over ten recognized histological subtypes of RCC but malignancies of chromophobe, kidney renal papillary cell carcinoma (KIRP), and the kidney renal clear cell carcinoma (KIRC) are the three most common subtypes. Among these subtypes, KIRP has the second highest morbidity rate (10%-15% of RCC cases), while KIRC has the highest incidence (75%-80% in RCC[1-5]). About 30% of RCC patients present with distant metastasis at diagnosis and have a poor prognosis. In clinical studies, patients with KIRC and malignancies of chromophobe often have ideal results. However, patients who were diagnosed with KIRP frequently experience significantly worse clinical outcomes[6-8]. Because most of the RCC presented are the KIRC subtype, researchers have a relatively good understanding of KIRC pathogenesis. The KIRP subtype has been less well studied than KIRC, so what we know is very limited [9-10]. Many therapies for advanced RCC are based on blocking known KIRC pathways using mTOR inhibitors and tyrosine kinase inhibitors to regulate the HIF1α and VEGF pathways, however, there are very few treatments for KIRP.

KIRP is a renal parenchyma malignant tumor, including two different subtypes (type 1 and type 2), which is often observed as papillary or tubulopapillary architecture [11]. Just like the KIRC, VEGF inhibitors and mTOR inhibitors have been developed based on the understanding of specific molecular sites [12]. Although researchers are beginning to develop therapeutic targets for KIRP, such as foretinib and capozantanib, these drugs are specific for type 1 KIRP but not the more aggressive type 2 KIRP[13-14]. Therefore, we must identify new and powerful molecular markers for prediction and treatment sites which can help in the development of new targeted drugs specific for KIRP.
Although cancer occurrence and development mainly depend on the alteration of tumor-associated genes, epigenetic changes such as the DNA methylation of tumor-related genes play an important role in the molecular barrier against tumor development[15-16]. DNA methylation is often considered a mechanism of gene silencing and it functions directly in many cellular processes such as embryonic development, transcription, genomic imprinting, and X-chromosome inactivation[17-19]. DNA methylation signatures have already been used in the early diagnosis and prognosis of cancers. For example, in breast cancer, the poor prognosis in patients may be correlated with CDH1 promoter methylation[20]. In addition, the DNA methylation of the promoter regions of P16, CDH13, APC, and RUSSF1A in stage I patients with non-small-cell lung cancer may be associated with early recurrence[21, 22].

There are also a large number of methylation biomarkers that have been proposed for the prediction of RCC[23], including the single methylation biomarkers for prognosis such as CRHBP[24], RCVRN[25], AR[7], CDO1[26], BMP-2[27], KEAP1[5], and DAB2IP[28]. While promising, tumorigenesis is a complex process that requires the involvement of multiple genes, thus many of these biomarkers are imperfect[29]. Considering that the occurrence and development of KIRP is a complex process that requires the joint regulation of multiple omics, it is necessary to establish a molecular marker model with high sensitivity and strong predictive ability to elucidate the prognosis of KIRP.

In this study, we aimed to find potential survival-related DNA methylation sites signatures in KIRP, which may pave the way for the development of novel prognostic markers and therapeutic targets for KIRP.

Methods
DNA methylation profiling and gene expression datasets of KIRP patients
In the current study, the DNA methylation profiling (Illumina Human Methylation 450K Bead Chip Array) and gene expression datasets (Illumina HiSeq RNA Seq V2) were downloaded from the TCGA database. A total of 276 KIRP and 45 control specimens were enrolled in the methylation dataset, while there were 289 cases and 32 controls in the gene expression dataset; both datasets contain clinical data, including survival time, status, gender, age, and clinical stage. The clinical information of
methylation data is shown in Table 1. Other DNA methylation data were retrieved from the Gene Expression Omnibus (GEO) database (GSE126441, n=14), which were used to validate the methylated level of signature genes. To improve the data accuracy, DNA methylation sites on sex chromosomes were excluded. Genes with missing expression values in >30% of samples or patients were removed, and the remaining missing values were entered by the k-nearest neighbour method. Genes whose RPKM expression values were 0 in all samples were excluded[30]. The technical route to select the DNA methylated sites signature is shown in Fig. 1.

Identification of DMGs and DEGs associated with KIRP
To identify the differentially methylated genes (DMGs), we adopted the Benjamini-Hochberg false-discovery rate (FDR) method to adjust the $P$ value for each gene. The DMGs were identified by a fold change $>2$, $p$-value $<0.05$, $FDR<0.05$, and Beta value $>0.1$. The differentially expressed genes (DEGs) were identified by a fold change $>2$, $p$-value $<0.05$, $FDR<0.05$, and $FPKM >1$.

After identifying multiple DMGs and DEGs from these datasets, we screened nine hub genes, which are genes both differentially expressed and enriched in differential methylation, between the DMGs and DEGs.

Constructing a prognostic DNA methylation signature in the training dataset
Statistics were employed to build a model based on reports of a better method to construct a signature module [31-32]. Gene methylation often occurs at specific loci, and the methylation of the gene is composed of multiple methylation sites, so in order to make the detection more accurate, we looked for methylation sites of hub genes, and then identified the sites associated with survival. Methylation sites were validated in the GEO dataset. After identifying the methylation sites of hub genes, we randomly divided all the KIRP methylation samples into two groups, the test group (87 cases) and training group (174 cases). The two groups were separate and uncrossed. Univariate Cox proportional hazards regression analysis was used to identify the association between survival time/status and each methylation site in the training data set [33]. In order to screen the most powerful and accurate DNA methylation sites to predict KIRP prognosis, multivariate Cox regression analysis was then used to build a model to assess the prognosis risk according to the following
expression: (see Formula 1 in the Supplementary Files)

where N represents the number of prognostic methylation gene sites, \( \eta \) is the methylation value of the

gene sites, and \( \beta \) is a single factor Cox regression coefficient. When the coefficient of the \( \beta < 0 \), we

defined it as a favorable prognosis site, while the sites with the coefficient of \( \beta > 0 \) were considered as

a poor prognosis site. Risk Score (RS) is the multi-node weighted sum of risk scores.

**Statistical analysis**

The selected methylated sites were used to construct a risk model. KIRP patients were dichotomized

into either high risk or low risk groups in the training dataset, the median risk score was used as a
cutoff value. Kaplan-Meier survival analysis and ROC analysis were used to validate the effective

prognostic ability of the methylation gene site signatures. We then validated the prognostic ability of
the DNA methylation signature in the test dataset. Furthermore, multivariable Cox regression analysis
was carried out to identify whether the DNA methylation signature was an independent factor in

survival prediction; we considered \( P < 0.05 \) indicate a statistically significant difference. All analyses

were performed with the R statistical program (version 3.5.1).

**Generating the nomogram**

We generated a nomogram by using the "RMS" package of R software. The nomogram concordance

index (C-index) of all patients was obtained by multivariate Cox regression analysis. The higher the C-

index, the more accurate the prediction. The nomogram was used to calculate the total score of each

patient. Overall scores were then used to predict 1-year, 3-year, and 5-year survival rates[34].

**Functional annotation of the selected DNA methylation signature genes**

In order to further study the function of survival-related DNA methylation signature genes, we used
gene ontology (GO) analysis (http://www.geneontology.org) to investigate the roles of all the selected
genes, and KEGG pathway analysis (http://www.genome.jp/kegg/) to determine the significant
pathways. Fisher’s exact test and chi-square tests were used to select significant GO and pathway
categories, with the threshold of significance of \( P \leq 0.05 \).

**Results**

**Identification of DMGs and DEGs associated with KIRP**

After preprocesing the methylation dataset, there were 261 cancerous tissues remaining. We

identified the DEGs and DMGs in the two datasets. To identify the KIRP-related DMGs, we performed
comparisons between 276 cancerous tissues and 45 adjacent tissues from KIRP patients. A total of 88 DMGs (Table S1) were identified in the methylation dataset (p<0.05; Δβ>0.1), among these there were 48 hypomethylated genes and 40 hypermethylated genes. For the DEGs identified, we compared the 289 cases and 32 controls in the gene expression dataset. In total, we obtained 5109 DEGs (Table S2) of which 3076 were upregulated and 2033 were downregulated. After identification of the DMGs and DEGs, there were nine overlapping genes with hypomethylated-high-expression and hypermethylated-low-expression, which contained seven hypomethylated-high-expression and two hypermethylated-low-expression genes as described in Fig. S1; the nine hub genes are shown in Table S3.

Identifying the four DNA methylation sites signature in the training group
The 261 patients were randomly divided into two groups (training group, n=174; test group, n=87) to identify and test the prognostic methylated gene sites found in the KIRP patients. In total, we identified 47 methylation sites (Table S4) in the nine hub genes. Then, univariate Cox proportional hazards regression analysis was conducted in the training group to identify the methylation sites significantly associated with overall survival time from the 47 sites. Eight methylated sites were significantly related to the survival of KIRP patients (P < 0.05, Fig. 2a, Table S5). In order to select the greatest prediction power signature, we conducted multivariable Cox regression analysis and built a model with the four methylated gene sites set (cg04448376, cg24387542, cg08548498, and cg14621323, Fig. 2b) to assess the prognosis risk. The risk score (RS, Table S6) was determined as follows: (see Formula 2 in the Supplementary Files)

\[ RS = \text{meth}_1 \times \text{meth}_2 + \text{meth}_3 \times \text{meth}_4 \]

RS and meth are the risk score and the methylation value, respectively.

Identification of the survival power of the DNA methylation signature
Each patient got a risk score from the selected methylated signature, and the median risk score was used as the cut off to divide the training group patients into either the low-risk group (n = 87) or high-risk group (n =87). Kaplan-Meier survival analysis showed that the overall survival (OS) rate of the low-risk group was significantly higher than that of the high-risk group (OS rate: 97.7% vs. 75.9%, log-rank test P<0.001; Fig. 3a). To validate the prediction power of the DNA methylation signature, we
validated it in the test group using the same prognostic risk score model, and found significant differences between the high-risk and low-risk groups (Fig. 3b). In the test dataset, the high-risk group had a significantly lower OS rate than the low-risk group (OS rate: 69.8% vs. 90.9%, log-rank test P=0.032).

The four methylation site signature has great survival predictive power
To test the predictive ability of the DNA methylation signature model, we conducted a separate ROC analysis, which showed high predictive ability of the four methylation signature sites in the training group (AUC_{Signature}=0.791, Fig. 3c); this further shows that the signature in our study is a new, highly accurate prognostic prediction marker. Similar results were found in the test group (AUC_{Signature}=0.704, Fig. 3d).

Nomogram of combined methylated sites signature and clinical variables predict patients’ OS
Our multivariate Cox regression model demonstrated that the predictive power of the signature risk score was independent of clinical characters (High-risk group vs. Low-risk group, HR = 1.40, 95% CI: 1.01–2.00, P=0.045, Fig. 4a). According to the above analysis results, we developed a methylated gene sites nomogram, which combined the clinical-related factors (stage, age, and sex) and methylated gene sites signature. In the training group, the calibration chart of the five-year operating system is well predicted (Fig. 4b).

Validated methylation sites in independent GEO cohorts
To confirm the four-methylation site pattern in different populations, we evaluated the samples (4 patients vs. 10 normal) in GSE126441 (Table S7). It showed that cg04448376 and cg14621323 have been down regulated and cg08548498 and cg24387542 have been up regulated in patients vs. normal (Fig. 5a,b,c,d), which is the same methylation pattern in the TCGA dataset. GO and KEGG functional annotation showed that the survival-related DNA methylation signature genes were significantly enriched in only three different GO terms (P<0.05). The four genes were mainly enriched in protein binding, an integral component of membrane and cytoplasm. The four methylated sites signature may participate in tumorigenesis by regulating cellular metabolic processes.

Discussion
KIRP reallenge due to high histologic heterogeneity, poor prognosis, and limited treatment options.

KIRP is the second most prevalent phenotype of RCC[35], however, the carcinogenesis mechanism of KIRP is not fully understood. Much of the previous research on KIRP genes has focused on some known cancer-related genes of KIRC. There is a lack of epigenetic biomarkers, and most of the prognosis of KIRP biomarker research are focused on the mRNA, IncRNA, and miRNA. For instance, Lan et al. identified seven lncRNAs that could predict the prognosis of KIRP[8]; Luo et al. identified hsa-mir-3199-2 and hsa-mir-1293 as novel prognostic biomarkers for KIRP[36]; and Gao et al. found that five mRNAs (CCNB2, IGF2BP3, KIF18A, PTTG1, and BUB1) can predict KIRP patient survival.

Although some prognostic markers of KIRP have been found in previous studies, the results are not consistent and there is no analysis at multiple omics levels. Therefore, reliable molecular signatures are needed to predict the survival of KIRP patients.

In our study, we identified 47 methylated gene sites from nine differentially methylated genes (DMGs), with opposite differential expression patterns. We used various statistical approaches to identify a four methylated sites signature from the 47 methylated sites. The signature that we selected can separate the KIRP patients into high-risk and low-risk groups with significantly different survival times in the training and test datasets, indicating it has a powerful prediction ability. The independence of the selected DNA methylation genes signature in predicting OS in the entire dataset was identified using multivariable Cox regression analysis, which confirmed that the risk score of DNA methylation sites signature was independent of OS.

The ROC curve showed that the AUC is 0.791 in the training group and 0.742 in the test group. Considering that larger AUC usually indicates better prediction power, this result further demonstrated that the DNA methylation signature in our study is a high accuracy novel prognostic marker and has important clinical value. In addition, our DNA methylation sites signature did not depend on other clinical features. Moreover, we validated the methylation gene sites signature and methylation sites in the TCGA and GEO cohorts and demonstrated their ability to predict overall survival of KIRP patients. We also established a methylation gene sites nomogram including methylation gene sites signature and clinical-related risk factors (e.g. stage and age) to predict OS.
So, our study results help in understanding the development KIRP and for developing tailored therapy, and ultimately may contribute to an increase in survival rates of KIRP patients.

In addition, we analyzed the function of the selected DNA methylation genes. The four methylation sites cg04448376, cg24387542, cg08548498, and cg14621323, were located in UTY, LGALS9B, SLPI, and PFN3, respectively. SLPI is a gene encoding secretory leukocyte protease inhibitor, a 11.7 KDa serine protease inhibitor, and is one of the members of the whey acidic protein four-disulfide core family[37, 38]. SLPI can reduce the activities of trypsin, neutrophil elastase, chymotrypsin and cathepsin G[39]. Therefore, SLPI may be a potential tumor marker to predict the prognosis[39].

Previous studies have shown that SLPI is related to tumor metastasis. In some high-risk, aggressive or metastatic tumors, such as pancreatic, uterine cervix, papillary thyroid, and ovarian cancers, SLPI was often found to be highly expressed[40–41]. However, in bladder tumors, nasopharyngeal carcinoma and some breast cancers, SLPI has a low expression. SLPI has high expression in gastric cancer cells with serosa invasion, and SLPI overexpression in gastric cancer cell lines can improve the cell migration and invasion rate[38]. These observations are entirely consistent with the previous observation that the expression of SLPI in tumors is often associated with poor prognosis. As far as we know, the present study is the first report of SLPI methylation sites as a prognostic biomarker in human KIRP. SLPI is hypomethylated and overexpressed in this report just like the previous study demonstrated, so we believe that SPLI is a favorable biomarkers for prognosis.

UTY is located on the Y chromosome and can encode a demethylase and was reported to be an epigenetic-related gene. UTY is essential in the development of teratoma through regulation of epigenetic changes[42–43]. In urothelial bladder cancer (UBC), 22.8% (8/35) of patients were found to have a reduced UTY copy number and cell proliferation was found to increase in a UTY knockout. UTY also plays an important role in some regulatory pathways, such as the NF-B and p53 pathways[44, 45]. In this study, we showed that methylation of UTY was significantly associated with KIRP survival, and that UTY can act as a survival-related methylation biomarker for KIRP.

For LGALS9B and PFN3, there is very little known about their regulatory mechanisms. The LGALS9B gene was initially thought to represent a pseudogene of galectin 9, however, the association between
it and tumors is unclear. This gene is one of two similar loci on chromosome 17p similar to galectin 9 and is now thought to be a protein-encoding gene. We have found that its functions are primarily associated with protein binding. Thus, we suspect that it is similar in function to galectin 9. Galectin-9 was reported to be related to metastasis and immunosuppression. In terms of its role in cancer, galectin-9 can affect different aspects in the process of tumor growth and aggressiveness, such as metastasis and immunomodulation[46–47]. In breast carcinoma, liver cancer and cervical tumors, LGALS9 expression affects disease prognosis[48–51]. PFN3, one of the isoforms of Profilin, is an actin binding protein. Previous studies show that PFN3 is expressed in the brain, testis, and kidney[52]. Genetic variation of PFN3 is significantly related to nephrolithiasis of Japanese individuals[53]. Although the functions of LGALS9B and PFN3 are not very clear, they are significantly associated with KIRP survival. Our study indicates that UTY, LGALS9B, SLPI, and PFN3 have important roles in KIRP. The limitations of this study need to be recognized. First, the samples of our study are entirely retrospective and inherent biases may influence the results. Hence, we may have lost signatures that are potentially correlated with KIRP survival. Secondly, we have not further searched the mechanism of action of these DNA methylation genes in KIRP. Finally, although we identified the selected DNA methylation sites as a powerful prediction signature, applying it in a clinical setting will require more research. Despite these drawbacks, the significant and consistent correlation between our four methylated site signature and overall survival in two independent datasets indicated that it is a potentially powerful prognostic marker for KIRP.

Conclusions
In summary, we identified a novel methylated sites signature to predict prognosis in KIRP. We confirmed this signature could serve as potential robust and specific biomarker in the prognosis prediction and tailored therapy for KIRP patients.

Abbreviations
KIRP: kidney renal papillary cell carcinoma; RCC: epithelial renal cell carcinoma; OS: overall survival;
AUC: Area under the curve; ROC: Receiver operating characteristic;

Declarations

Acknowledgements
Author contributions

YLW contributed to the conception and design of the study and the collection of the clinical and TCGA data of the patients. YLW and YYZ contributed to the interpretation of the data (statistical and computational analysis) and the writing of the manuscript. YYZ contributed to the review and revision of the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

All data used and analyzed during this study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The contents of this article are data mining from the The Cancer Genome Atlas database (TCGA) database. The TCGA database is open and shared and doesn't require informed patient consent.

Consent for publication

Not Applicable.

Competing interests

The authors declare no competing interests.

Author details

1. Department of urinary surgery, Yantai Affiliated Hospital of Binzhou Medical University, YanTan, ShangDong, 0535, China.

2. Office of quality and safety management, Yantai Affiliated Hospital of Binzhou Medical University, YanTan, ShangDong, 0535, China.

References

1. Foshat M, Eyzaguirre E: Acquired Cystic Disease-Associated Renal Cell Carcinoma: Review of Pathogenesis, Morphology, Ancillary Tests, and Clinical Features. Archives of Pathology & Laboratory Medicine 2017, 141(4):600-606.
2. Zhang T, Gong J, Maia MC, Pal SK: Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma. 2017.

3. Ning XH, Gong YQ, He SM, Li T, Wang JY, Peng SH, Chen JC, Liu JY, Qi NN, Guo YL: Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues. Oncotarget 2016, 8(2).

4. Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH: A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma. European Urology 2016, 71(3):426.

5. Fabrizio FP, Costantini M, Copetti M, La TA, Sparaneo A, Fontana A, Poeta L, Gallucci M, Sentinelli S, Graziano P: Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma. Oncotarget 2017, 8(7):11187-11198.

6. D ME: Utilization of Sunitinib for Renal Cell Cancer: an Egyptian University hospital experience. Asian Pac J Cancer Prev 2016, 17(7):3161-3166.

7. Zhao H, Leppert JT, Peehl DM: A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data. Plos One 2016, 11(1):e0146505.

8. Lan H, Zeng J, Chen G, Huang H: Survival prediction of kidney renal papillary cell carcinoma by comprehensive LncRNA characterization. Oncotarget 2017, 8(67):110811-110829.

9. Linehan WM: The Genetic Basis of Kidney Cancer: Implications for Management and Use of Targeted Therapeutic Approaches. European Urology 2012, 61(5):896-898.

10. Linehan WM, Ricketts CJ: The metabolic basis of kidney cancer. In: Seminars in Cancer Biology: 2013.
11. Montironi R, Cheng L, Scarpelli M, Lopez-Beltran A: Pathology and Genetics: Tumours of the Urinary System and Male Genital System: Clinical Implications of the 4th Edition of the WHO Classification and Beyond. European Urology 2016, 70(1):120-123.

12. Pyrhönen SO: Systemic therapy in metastatic renal cell carcinoma. Scandinavian Journal of Surgery Sjs Official Organ for the Finnish Surgical Society & the Scandinavian Surgical Society 2004, 93(2):156.

13. Choueiri TK, Pal SK, Mcdermott DF, Morrissey S, Ferguson KC, Holland J, Kaelin WG, Dutcher JP: A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Annals of Oncology 2014, 25(8):1603-1608.

14. Choueiri TK, Ulka V, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Sandy S, Stein MN, Adams LM: Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of Clinical Oncology 2013, 31(2):181-186.

15. Lorincz AT: Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Review of Molecular Diagnostics 2014, 14(3):293-305.

16. Christoph P, Pfister SM, Lindroth AM, Olga B, Rainer C, Peter L: Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nature Reviews Genetics 2013, 14(11):765-780.

17. Guo H, Zhu P, Yan L, Li R, Hu B, Lian Y, Yan J, Ren X, Lin S, Li J: The DNA methylation landscape of human early embryos. Nature 2014, 511(7511):606-610.

18. Robertson KD: DNA methylation and human disease. Nat Rev Genet 2005, 6(8):597-610.

19. Xu X: DNA methylation and cognitive aging. Oncotarget 2015, 6(16):13922-13932.

20. Liu J, Sun X, Qin S, Wang H, Du N, Li Y, Pang Y, Wang C, Xu C, Ren H: CDH1 promoter
methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer. *Oncology Letters* 2016, 11(4):2635.

21. Brock MV, Hooker CM, Emi OM, Yu H, Mingzhou G, Stephen A, Sabine GC, Steven P, Edward G, Genevieve P: DNA methylation markers and early recurrence in stage I lung cancer. *N Engl J Med* 2008, 358(11):1118-1128.

22. Iii CHS, Iii WMR, Jones PA: DNA Methylation and cancer; 1993.

23. Golovastova MO, Korolev DO, Tsoy LV, Varshavsky VA, Xu WH, Vinarov AZ, Zernii EY, Philippov PP, Zamyatnin AA: Biomarkers of Renal Tumors: the Current State and Clinical Perspectives. *Current Urology Reports* 2017, 18(1):3.

24. Tezval H, Dubrowskaja N, Peters I, Reese C, Serth K, Atschekzei F, Hennenlotter J, Stenzl A, Kuczyk MA, Serth J: Tumor Specific Epigenetic Silencing of Corticotropin Releasing Hormone -Binding Protein in Renal Cell Carcinoma: Association of Hypermethylation and Metastasis. *Plos One* 2016, 11(10):e0163873.

25. Golovastova MO, Tsoy LV, Bocharkina AV, Korolev DO, Gancharova OS, Alekseeva EA, Kuznetsova EB, Savvateeva LV, Skorikova EE, Strelnikov VV: The cancer-retina antigen recoverin as a potential biomarker for renal tumors. *Tumor Biology* 2016, 37(7):1-9.

26. Deckers IA, Schouten LJ, Van NL, van Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman JG, Pa VDB: Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome. *Clinical Cancer Research An Official Journal of the American Association for Cancer Research* 2015, 21(15):3492.

27. Yozo M, Hiroshi H, Naoko A, Miho H, Hiroaki Y, Inik C, Shinichiro F, Soichiro Y, Varahram S, Guoren D: Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic
pathways. Oncotarget 2015, 6(11):9577-9591.

28. Wang ZR, Wei JH, Zhou JC, Haddad A, Zhao LY, Kapur P, Wu KJ, Wang B, Yu YH, Liao B: Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget 2016, 7(21):31508-31519.

29. Brooks JD: Translational genomics: the challenge of developing cancer biomarkers. Genome Research 2012, 22(2):183.

30. Juan X, Yongsheng L, Jianping L, Tao P, Na D, Zishan W, Tingting S, Jinwen Z, Lihua W, Xia L: The mRNA related ceRNA-ceRNA landscape and significance across 20 major cancer types. Nucleic Acids Research 2015, 43(17):8169-8182.

31. Hu S, Yin X, Zhang G, Meng F: Identification of DNA methylation signature to predict prognosis in gastric adenocarcinoma. J Cell Biochem 2019.

32. S H, X Y, G Z, F M: Identification of DNA methylation signature to predict prognosis in gastric adenocarcinoma. Journal of cellular biochemistry 2019, undefined(undefined):undefined.

33. Guo JC, Wu Y, Chen Y, Pan F, Wu ZY, Zhang JS, Wu JY, Xu XE, Zhao JM, Li EM et al: Protein-coding genes combined with long noncoding RNA as a novel transcriptome molecular staging model to predict the survival of patients with esophageal squamous cell carcinoma. Cancer Commun (Lond) 2018, 38(1):4.

34. YS W, H L, D C, Z Y, B Z, Y J, G R: A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer. Gene 2019, 697(undefined):86-93.

35. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE: The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. European Urology 2016, 70(1):106-119.

36. Luo W, Wang L, Luo MH, Huang YZ, Yang H, Zhou Y, Jia HT, Wang XX: hsa-mir-3199-2 and hsa-mir-1293 as Novel Prognostic Biomarkers of Papillary Renal Cell Carcinoma
by COX Ratio Risk Regression Model Screening. *Journal of Cellular Biochemistry* 2017.

37. Mckiernan PJ, Mcelvaney NG, Greene CM: SLPI and inflammatory lung disease in females. *Biochemical Society Transactions* 2011, 39(5):1421-1426.

38. Sallenave JM: Antimicrobial activity of antiproteinases. *Biochem Soc Trans* 2002, 30(2):111-115.

39. Sugino T, Yamaguchi T, Ogura G, Kusakabe T, Goodison S, Homma Y, Suzuki T. The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway. *Journal of Pathology* 2010, 212(2):152-160.

40. Nick D, Gholamreza HG, Jing Z, Lea B, Patrick DB, Hilde R: Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. *Proc Natl Acad Sci U S A* 2003, 100(10):5778-5782.

41. Devoogdt N, Revets H, Ghassabeh GH, De BP: Secretory leukocyte protease inhibitor in cancer development. *Annals of the New York Academy of Sciences* 2010, 1028(1):380-389.

42. Bulićjakuš F, Ulamec M, Vlahović M, Sinčić N, Katušić A, Jurićlekić G, Šerman L, Krušlin B, Belicza M: Of Mice and Men: Teratomas and Teratocarcinomas. *Collegium Antropologicum* 2006, 30(4):921.

43. Bonner AE, Wang Y, You M: Gene Expression Profiling of Mouse Teratocarcinomas Uncovers Epigenetic Changes Associated with the Transformation of Mouse Embryonic Stem Cells. *Neoplasia* 2004, 6(5):490-502.

44. Carr SM, Munro S, La Thangue NB: Lysine methylation and the regulation of p53. *Essays in Biochemistry* 2012, 52(1):79.

45. Tao L, Maojing Y, De-Bin H, Han W, Ozer GH, Gourisankar G, Stark GR: Role of lysine methylation of NF-κB in differential gene regulation. *Proceedings of the National
46. Heusschen R, Thijssen VL, Griffioen AW: Galectin-9 in tumor biology: A jack of multiple trades. *Biochim Biophys Acta* 2013, 1836(1):177-185.

47. Liu FT, Rabinovich GA: Galectins as modulators of tumour progression. *Nature Reviews Cancer* 2005, 5(1):29-41.

48. Akemi I, Akira Y, Keiichi K, Minoru K, Dage L, Yukako S, Masako S, Nozomu N, Takanori N, Hiroyasu Y: Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. *Clinical Cancer Research An Official Journal of the American Association for Cancer Research* 2005, 11(8):2962-2968.

49. Zhao-Yang Z, Jia-Hong D, Yong-Wei C, Xian-Qiang W, Chong-Hui L, Jian W, Guo-Qiang W, Hai-Lin L, Xue-Dong W: Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. *Asian Pac J Cancer Prev* 2012, 13(6):2503-2509.

50. Toshiro K, Yumiko K, Akira Y, Masako S, Mohammad Jainul A, Nozomu N, Hiroki S, Takanori N, Tomomichi O, Mitsuomi H: Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. *International Journal of Cancer* 2002, 99(6):809-816.

51. Liang M, Ueno M, S, Arikawa T, Shinonaga R, Zhang S, Yamauchi A, Hirashima M: Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. *Journal of Cancer Research & Clinical Oncology* 2008, 134(8):899-907.

52. Tariq N, Basharat Z, Butt S, Baig DN: Distribution analysis of profilin isoforms at transcript resolution with mRNA-seq and secondary structure in various organs of *Rattus norvegicus*. *Gene* 2016, 589(1):49-55.

53. Takahiro Y, Atsushi O, Yuji U, Masayuki U, Kentaro M, Yasue K, Keiichi T, Shoichi S, Yoshihito H, Yoshikazu S: A replication study for three nephrolithiasis loci at 5q35.3,
Table 1

Table 1 Summary of patient demographics and characteristics

| Characteristic | Training (N=174) | Test (N=87) |
|----------------|------------------|------------|
| Gender         |                  |            |
| Female         | 43               | 26         |
| Male           | 131              | 58         |
| Age            |                  |            |
| <62 years      | 78               | 41         |
| ≥62 years      | 96               | 46         |
| Stage          |                  |            |
| i              | 107              | 52         |
| ii             | 15               | 6          |
| iii            | 35               | 18         |
| iv             | 8                | 5          |
| Vital status   |                  |            |
| Living         | 151              | 70         |
| Dead           | 23               | 17         |

Additional File Legends

Fig.S1. the methylated sites of nine intersection genes between DMGs and DEGs

Table S1 DMGs

Table S2 DEGs

Table S3 the nine hub genes

Table S4 the methylated sites of nine hub genes

Table S5 Univariate Cox proportional hazards regression analysis (P <0.05) of the methylated sites data in the training dataset

Table S6 The signature riskScore composed of four sites combinations in the training and test dataset.

Table S7 the expression of four methylated sites in GSE126441

Figures
Figure 1

Flowchart of the study

Figure 2

Univariable (a) and multivariable Cox (b) regression analysis of the association between the methylated sites signature and the survival of KIRP patients in training group.
Methylated sites signature predicts prognosis of KIRP patients (a, b) Kaplan–Meier survival curves classified KIRP patients into high-risk and low-risk groups using the sites signature in the training and test datasets. P-values were calculated by log-rank test. (c, d) Results of receiver operating characteristic (ROC) analysis.
Figure 4

Multivariable Cox (a) regression analysis and nomogram of combined methylated sites signature and clinical variables predict patients' OS (b)
Validated methylation sites of signature in independent GEO cohorts.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- TableS4.xls
- Fig.S1.tif
- Formula 1.jpg
- Formula 2.jpg
- TableS6.xls
- TableS5.xls
- TableS2.xls
- TableS1.xls
- TableS3.xls
- TableS7.xls